Medtronic Lifts Outlook as Revenue Jumps

Medtronic reported robust Q1 FY26 results, achieving 4.8% organic revenue growth and adjusted EPS of $1.26, surpassing guidance, and subsequently raised its full-year FY26 EPS outlook to $5.60-$5.66. This strong performance was primarily fueled by nearly 50% organic growth in its Cardiac Ablation Solutions business, driven by the success of Pulsed Field Ablation (PFA) products, alongside significant anticipation for its Renal Denervation (RDN) Symplicity system as it awaits imminent CMS national coverage. Additionally, the company announced strategic board and governance enhancements in collaboration with Elliott Management, aimed at accelerating operational efficiency and long-term value creation in anticipation of its Diabetes business separation and a mid-2026 Investor Day.

Analysis

Medtronic has demonstrated significant operational momentum, reporting Q1 FY26 organic revenue growth of 4.8% and an adjusted EPS of $1.26, which exceeded prior guidance. This outperformance prompted management to raise full-year FY26 EPS guidance to a range of $5.60-$5.66. The primary growth engine is the Cardiac Ablation Solutions (CAS) business, which posted nearly 50% year-over-year organic revenue growth, fueled by strong adoption of its Pulsed Field Ablation (PFA) system in a market expanding at over 25% annually. Concurrently, the company is on the cusp of a major catalyst with its Symplicity system for Renal Denervation (RDN), awaiting a pivotal CMS national coverage decision by October 8, which would unlock an addressable market of 18 million U.S. patients. Further supporting the investment thesis, Medtronic has partnered with activist investor Elliott Management to overhaul its board, adding two experienced directors and establishing new Growth and Operating committees. This governance reset is designed to enforce greater capital allocation discipline and operational rigor, signaling a clear commitment to accelerating shareholder value creation ahead of the planned Diabetes business separation and a strategic Investor Day in mid-2026.

Key Decisions for Investors

• Investors should recognize the current earnings power driven by the rapidly growing PFA business, which is securing market share and supports the newly raised full-year guidance.
• The upcoming CMS national coverage decision for the Symplicity Renal Denervation system, expected by October 8, represents a critical near-term catalyst that could significantly re-rate the stock by unlocking a multi-billion dollar market.
• The board and governance changes, instigated in partnership with Elliott Management, signal a heightened focus on operational efficiency and capital discipline, which could lead to margin expansion and improved long-term shareholder returns.
• Monitor progress on the Diabetes business separation and anticipate the mid-2026 Investor Day for crucial updates on the post-spin portfolio strategy and new financial targets, which will define the company's long-term value proposition.